Post-Traumatic Stress Disorder Therapeutics Market By Drug Class (Antidepressants, Anti-Anxiety Drugs, Other Drug Classes, Pipeline Candidate) - Growth, Future Prospects & Competitive Analysis, 2018 - 2026

Industry Outlook

The global post-traumatic stress disorder therapeutics market expected to reach 10,679.5 Mn by 2026 with CAGR of 4.5% during the forecast period from 2018 to 2026. Antidepressants including SSRIs (Zoloft and Paxil) are among the first line of treatment for PTSD, dominated the global market in 2017 and projected to retain its dominance during the forecast period. North America dominated the PTSD therapeutics market with more than 50% of market share for the year 2017. Higher awareness about healthcare and treatment among the general population, better rate of self-reporting are some macro factors contributing to the dominance of North America in the global market. Post-traumatic stress disorder (PTSD) is a vastly prevalent disorder but a rarely recognized syndrome that is characterized by some serious reactions such as fear, helplessness, and horror. According to the Diagnostic and Statistical Manual of Mental Disorders, PTSD is categorized as acute if symptoms are within three months of the trauma, and chronic if symptoms occur between three to six months of the trauma.

Post-traumatic stress disorder is classified as anxiety disorder and symptoms of PTSD can develop either immediately following a traumatic event or during the course of time. The symptoms of PTSD comprise abnormal mood swings, avoidance of stressful incidents and so on. PTSD occurs at any age, irrespective of gender; however, the prevalence of PTSD is higher in women. As reported by PTSD United, an estimated one in every eight women develops PTSD in a lifetime, thus making females twice more likely than males. The prevalence of PTSD in the United States is 3.5%.

Growing prevalence of post-traumatic stress disorder is the chief factor driving global post-traumatic stress disorder drugs market. Increase in events such as wars, combats, and interpersonal violence has been a major contributor to the growing prevalence of PTSD. Factors such as growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

The United States dominated the global PTSD therapeutics market. Moreover, the domicile of prominent players and swift approval of drugs in the region ensures the dominance of North America. Europe is identified as the second largest market due to the growing patient pool, greater awareness regarding availability and efficacy of therapeutics, and initiatives from government and non-government organizations to strengthen and develop healthcare infrastructure along with favorable reimbursement system. The awareness related to PTSD is low in the Asia Pacific compared to North America & Europe due to lack of diagnosis and criticality of mental disorders in general public.  

Market Synopsis

Post-Traumatic Stress Disorder Therapeutics Market

Antidepressant drugs leading the post-traumatic stress disorder therapeutics market

Currently, antidepressants including SSRIs (Zoloft and Paxil) are among the first line of treatment for PTSD, dominated the global market in 2017 and projected to retain its dominance during the forecast period from 2018 to 2026. Moreover, the prevalence of diseases is rising due to the increasing number of accidents and violence worldwide the global PTSD therapeutics market is expected to grow during the forecast period from 2018 to 2026.

Post-Traumatic Stress Disorder Therapeutics Market

Post-Traumatic Stress Disorder Therapeutics Market

Historical & Forecast Period

2016 – Historical Year

2017 – Base Year

2018-2026 – Forecast Period

This comprehensive study offers the analysis of every segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded Annual Growth Rate (CAGR) for each segment calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

Post-traumatic stress disorder therapeutics market study offers the existing market dynamics along with a quantitative analysis of the global market. The report elucidates the detailed outline of global post-traumatic stress disorder therapeutics market by classifying the market in terms of drug class and geography. The objective of publishing this extensive research report is to support the healthcare professionals and market investors in making strategic initiatives and better conclusions in the post-traumatic stress disorder therapeutics market.

Drug Class Segment (2016–2026; US$ Mn)

  • Antidepressants
    • SSRIs
    • SNRIs
    • MAO Inhibitors
    • Tricyclic Antidepressants
  • Anti-anxiety Drugs
    • Beta-blockers
    • Benzodiazepines
  • Other Drug Class
    • Alpha-1 & Alpha-2 Receptor Antagonists
    • Atypical Antipsychotics
    • Anticonvulsants
  • Pipeline Candidates (Qualitative information)
    • SRX 246 (Phase II)
    • BNC 210 (Phase II)
    • Tonmya (Phase II)
  • Geography Segment (2016–2026; US$ Mn)
    • North America
      • United States
      • Canada
    • Europe
      • United Kingdom
      • Germany
      • Rest of Europe
    • Asia Pacific (APAC)
      • Japan
      • China
      • Rest of APAC
    • Latin America (LATAM)
      • Mexico
      • Brazil
      • Rest of LATAM
    • Middle East and Africa (MEA)
      • GCC
      • Rest of Middle East and Africa

Post-Traumatic Stress Disorder Therapeutics Market

This comprehensive study further describes the major qualitative market assessment factors including main market drivers, market trends, and restraints, to help in better understanding of global post-traumatic stress disorder therapeutics market. Every market assessment factor including market drivers, challenges, and opportunities are widely explained considering the existing market situation. This study fully maps the market players based on their strategies, market initiatives, business strength, and product offering. Moreover, the report offers attractive investment proposal based on the widespread geographical research. Main players profiled in the study include Pfizer, Inc., GlaxoSmithKline plc, Otsuka Pharmaceutical Co., Ltd, Novartis AG, AstraZeneca Plc, Azevan Pharmaceuticals, Inc., Bionomics Ltd., Tonix Pharmaceuticals Holding Corp., Apotex, Inc. among others.

Key questions answered in this report

  • What are the current market trends in the post-traumatic stress disorder therapeutics market and valued opportunities for the players?
  • How the regulatory framework affects the global as well as the regional markets?
  • Which is the prominent drug class in PTSD treatment market?
  • How does the FDA approval of products affect the global market?
  • What are the trend and market size in emerging markets such as Japan, Mexico, and Brazil?
  • Which is the largest and fastest growing regional market?
  • Which is the largest segment by drug class in the post-traumatic stress disorder therapeutics market?
  • Which is the fastest growing segment by drug class in the post-traumatic stress disorder therapeutics market?
  • Market assessment in terms of value.
  • Analysis of market strategies and competitive landscapes.
Choose License Type
Published Date:  Apr 2018
Category:  Pharmaceuticals
Report ID:   58727
Report Format:   PDF
Pages:   120
Rating:    4.5 (70)
Connect With Us
+1-408-641-3282
24/7 Research Support